Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company develops therapies that target the molecular mechanisms implicated in cancer. Its primary product includes Nexavar, a novel, oral multiple kinase inhibitor of tumor cell proliferation and angiogenesis for the treatment of individuals with advanced kidney cancer, targeting RAF, VEGFR-2, PDGFR-â, KIT, FLT-3, and RET. The company also develops a Phase I clinical trial product, PD 332991, a small molecule inhibitor of cyclin-dependent kinase. It has collaboration agreement with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or...